SCYNEXIS, Inc. Presents SCY-635 Data on HCV at International Liver Congress
4/25/2013 10:21:03 AM
More...
|
SCYNEXIS, Inc. and Immune Design Corporation Collaborate on Innovative Process for Vaccine Production Technology
4/10/2013 11:33:17 AM
More...
|
SCYNEXIS, Inc.'s Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments
11/12/2012 9:31:23 AM
More...
|
SCYNEXIS, Inc. to Report Phase 2a Study of SCY-635 for Treatment of HCV at American Association for Study of Liver Diseases
11/5/2012 9:17:07 AM
More...
|
SCYNEXIS, Inc. Announces Exclusive Licensing Deal for the Treatment of Canine Dry Eye
9/4/2012 9:54:10 AM
More...
|
SCYNEXIS, Inc. to Present on Screening Technology Used in Anti-Malarial Research at American Chemical Society National Meeting
8/20/2012 9:05:45 AM
More...
|
SCYNEXIS, Inc. Wants to Raise $25 Million by May
2/28/2012 8:37:37 AM
More...
|
Morria Biopharmaceuticals Plc Selects SCYNEXIS, Inc. to Support CMC Activities for MRX-4, a Novel Anti-Inflammatory Drug for Allergic Rhinitis
2/16/2012 8:41:39 AM
More...
|
MMV and SCYNEXIS, Inc. Offer 400 Active Compounds for Neglected Disease Drug Research at No Cost
12/19/2011 9:00:25 AM
More...
|
SCYNEXIS, Inc. Presents Data Demonstrating that SCY-635 Restores the Body’s Innate Immune Response to HCV and Could be an Effective Replacement for Recombinant Interferon
11/7/2011 11:23:38 AM
More...
|
|